KeyTec® TR-FRET Human SMARCA2 Binding Kit
Size:
Price: $
CAT.: A1090013D
The KeyTec® TR-FRET Human SMARCA2 Protein Binding Assay Kit is designed for screening ligands or inhibitors of wild‑type human SMARCA2 protein. This kit is a competitive immunoassay developed using KeyTec® TR‑FRET technology, offering advantages such as simple and rapid operation, high specificity, high sensitivity, and excellent reproducibility.
The principle is as follows: Solar Eu1‑conjugated anti‑Tag1 antibody specifically recognizes Tag1‑SMARCA2 protein, while HX2‑conjugated streptavidin (Streptavidin‑HX) recognizes biotinylated Bromodomain Ligand. When SMARCA2 protein binds to the Bromodomain Ligand, Solar Eu and HX are brought into close proximity, enabling energy resonance transfer between the donor and acceptor upon external light excitation. The degree of binding between the Bromodomain Ligand and SMARCA2 is determined by measuring the signal intensity at 665 nm. In the absence of inhibitors or competing ligands, the signal is at its maximum; as the concentration of added inhibitors or ligands increases, the signal gradually decreases. The TR‑FRET signal intensity is inversely proportional to the affinity of the inhibitor or ligand.
Standard curve
Validation results with different final concentrations of DMSO
Validation results in buffer systems with different pH values
| CAT. | Description | Size |
| A1090013D | KeyTec® TR-FRET Human SMARCA2 Binding Kit | 100 tests |
|
• 1 vial 8 µL/vial Tag1 - SMARCA2 • 1 vial 8 µL/vial Bromodomain Ligand • 1 vial 5 µL/vial mAb anti - Tag1 - Solar Eu • 1 vial 5 µL/vial Streptavidin - HX • 2 vials 2 mL/vial SMARCA2/4 Binding Assay Diluent Buffer（pH 8.0） • 1 vial 2 mL/vial SMARCA2/4 Detection Buffer（pH 8.0） |
||
| Certificate of Analysis | Limitations | Storage Conditions |
| LOT. | For research use only |
-60℃ or below |
The KeyTec® TR-FRET Human SMARCA2 Protein Binding Assay Kit is designed for screening ligands or inhibitors of wild‑type human SMARCA2 protein. This kit is a competitive immunoassay developed using KeyTec® TR‑FRET technology, offering advantages such as simple and rapid operation, high specificity, high sensitivity, and excellent reproducibility.
The principle is as follows: Solar Eu1‑conjugated anti‑Tag1 antibody specifically recognizes Tag1‑SMARCA2 protein, while HX2‑conjugated streptavidin (Streptavidin‑HX) recognizes biotinylated Bromodomain Ligand. When SMARCA2 protein binds to the Bromodomain Ligand, Solar Eu and HX are brought into close proximity, enabling energy resonance transfer between the donor and acceptor upon external light excitation. The degree of binding between the Bromodomain Ligand and SMARCA2 is determined by measuring the signal intensity at 665 nm. In the absence of inhibitors or competing ligands, the signal is at its maximum; as the concentration of added inhibitors or ligands increases, the signal gradually decreases. The TR‑FRET signal intensity is inversely proportional to the affinity of the inhibitor or ligand.
Standard curve
Validation results with different final concentrations of DMSO
Validation results in buffer systems with different pH values
| CAT. | Description | Size |
| A1090013S | KeyTec® TR-FRET Human SMARCA2 Binding Kit | 500 tests |
|
• 1 vial 40 µL/vial Tag1 - SMARCA2 • 1 vial 40 µL/vial Bromodomain Ligand • 1 vial 25 µL/vial mAb anti - Tag1 - Solar Eu • 1 vial 25 µL/vial Streptavidin - HX • 1 bottle 20 mL/bottle SMARCA2/4 Binding Assay Diluent Buffer（pH 8.0） • 1 bottle 20 mL/bottle SMARCA2/4 Detection Buffer（pH 8.0） |
||
| Certificate of Analysis | Limitations | Storage Conditions |
| LOT. | For research use only |
-60℃ or below |
The KeyTec® TR-FRET Human SMARCA2 Protein Binding Assay Kit is designed for screening ligands or inhibitors of wild‑type human SMARCA2 protein. This kit is a competitive immunoassay developed using KeyTec® TR‑FRET technology, offering advantages such as simple and rapid operation, high specificity, high sensitivity, and excellent reproducibility.
The principle is as follows: Solar Eu1‑conjugated anti‑Tag1 antibody specifically recognizes Tag1‑SMARCA2 protein, while HX2‑conjugated streptavidin (Streptavidin‑HX) recognizes biotinylated Bromodomain Ligand. When SMARCA2 protein binds to the Bromodomain Ligand, Solar Eu and HX are brought into close proximity, enabling energy resonance transfer between the donor and acceptor upon external light excitation. The degree of binding between the Bromodomain Ligand and SMARCA2 is determined by measuring the signal intensity at 665 nm. In the absence of inhibitors or competing ligands, the signal is at its maximum; as the concentration of added inhibitors or ligands increases, the signal gradually decreases. The TR‑FRET signal intensity is inversely proportional to the affinity of the inhibitor or ligand.
Standard curve
Validation results with different final concentrations of DMSO
Validation results in buffer systems with different pH values
| CAT. | Description | Size |
| A1090013L | KeyTec® TR-FRET Human SMARCA2 Binding Kit | 5,000 tests |
|
• 1 vial 400 µL/vial Tag1 - SMARCA2 • 1 vial 400 µL/vial Bromodomain Ligand • 1 vial 250 µL/vial mAb anti - Tag1 - Solar Eu • 1 vial 250 µL/vial Streptavidin - HX • 1 bottle 200 mL/bottle SMARCA2/4 Binding Assay Diluent Buffer（pH 8.0） • 1 bottle 120 mL/bottle SMARCA2/4 Detection Buffer（pH 8.0） |
||
| Certificate of Analysis | Limitations | Storage Conditions |
| LOT. | For research use only |
-60℃ or below |
English
![KeyTec® TR-FRET GDP loaded KRAS[G12D]/SOS1 Binding Assay kit](/uploads/image/20260713/A1090001S.webp "KeyTec® TR-FRET GDP loaded KRAS[G12D]/SOS1 Binding Assay kit")
